Stock Ticker

  • Loading stock data...

Gilead Sciences, Inc (NASDAQ:GILD) Speaks Out On The Trial Of Its Remdesivir Drug

Gilead Sciences, Inc (NASDAQ:GILD) is pleased to report about the success it is witnessing with its vaccine Remdesivir. The scientists have been working on the product in the hope that it would turn out to be the vaccine that would possibly help in dealing with COVID-19. Gilead has given an update outlining that it is ahead of schedule in terms of conducting the trial.

The COVID-19 pandemic has shaken the world, pushing governments to execute lockdown and curfews. Such decisions have resulted in major losses as many governments continue looking for more ways to protect citizens.

The move by Gilead may have something to do with a directive by President Trump for companies to participate in the fight against the deadly virus. The US leader had challenged leading companies, scientists, lawyers, and other prominent sectors to join hands to fight against a common enemy. Trump said that it would be a much better idea if they brought heads together to develop a common vaccine, instead of each one of them working separately.

One professor at the University of Nebraska Medical Center, known as Dr. Kalil, has elaborately spoken about the matter. He reveals that the National Institute of Allergy and Infectious Diseases (NIAID) was the one conducting the trial. He has heaped praised on the institute by outlining that it plays up to all the required scientific standards. According to the leader, these are standards that are believed to be good enough in making a proper determination on whether or not the product works.

Kalil says that the trial has been running on in a pretty organized way, taking into account the enrollment of about 500 persons. Half of these people have been receiving a placebo, whereas the other half has been subjected to the drug. In other words, these are two groups, each representing 50% of the total.

The official says that what interests them a huge deal is not only the statistical difference but also the quest to achieve a tremendous clinical improvement. Kalil expresses great optimism by outlining that somewhere in Mid-to-late May they may have succeeded at presenting some meaningful results.

Published by Christine Lawrence

Christine Lawrence is a financial analyst. She loves analyzing socioeconomic trends in the background of financial moves. She has overall seven years of experience in Auditing, Finance and Writing.



Recent Stories

SignUp Now For Our Featured Newsletter